Acute Effect of Photobiomodulation Therapy on Muscle Performance in Female Futsal Players

January 7, 2026 updated by: Andreo Fernando Aguiar, Universidade Norte do Paraná

Acute Dose-response Effect of Photobiomodulation Therapy on Muscle Performance in Female Futsal Players: a Randomized, Double-blind, Placebo-controlled, Crossover Study

Photobiomodulation therapy (PBMT) has recently been indicated as a potential therapeutic strategy in diverse health and sports contexts. However, its efficacy on muscle performance in female futsal players remains unknown. The purpose of this study was to investigate the dose-response effect of PBMT on muscle performance in female futsal players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Background: Photobiomodulation therapy (PBMT) has recently been indicated as a potential therapeutic strategy in diverse health and sports contexts. However, its efficacy on muscle performance in female futsal players remains unknown. The purpose of this study is to investigate the dose-response effect of PBMT on muscle performance in female futsal players. Methods: In a crossover design, fifteen female futsal athletes (age: 18-30 years) will be randomized to receive 1 of 4 PBMT conditions (placebo, 300, 900, and 1260 joules [J]) on four occasions, separated by a 2-wk washout period. PBMT treatments will be applied on the quadriceps muscle of both legs using a device containing 200 light-emitting diodes (LEDs), immediately before the following tests (dependent variables): countermovement jump (CMJ) (i.e., flight time as indicator of muscle power), maximum voluntary isometric contraction (MVIC) for the leg extension exercise (i.e., muscle strength), and 3 sets of repetitions-to-failure (i.e., local muscular endurance) for the 45º leg press exercise, with recording of rating of perceived exertion (RPE) after each set. The fatigue index will be determined by the number of repetitions between sets 1 and 3. Statistical analyses will be performe using IBM SPSS Statistics for Windows (version 24.0; IBM Corp., Armonk, NY). Data will be tested for normality and homogeneity using the Shapiro-Wilk's and Levene's tests, respectively. One-way ANOVA tests will be performed to evaluate the differences in the fatigue index, flight time, and peak and mean torque between the treatment conditions (placebo, 300, 900, and 1260 J). Changes over time and between treatment conditions in maximum number of repetitions and RPE will be analyzed with two-way repeated measures ANOVA. Violation of sphericity was corrected using the Greenhouse-Geisser method. When significant differences will be confirmed with the ANOVA, multiple comparison testing will be performed using the Bonferroni post hoc correction to identify these differences. Values will be expressed as mean (standard deviation and 95% confidence interval). The significance level was set at p < 0.05.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
15

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Paraná
      • Londrina, Paraná, Brazil, 86.041-140
        • Universidade Norte do Paraná

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age between 18 and 35 years
  • Playing futsal regularly for more than 1 year.

Exclusion Criteria:

  • Use of any ergogenic or anabolic supplement within 6 months prior to the start of the study,
  • Take any medication that may affect the ability to perform the physical tests,
  • Have any physical limitation (e.g. joint or muscle injury) that may affect the ability to perform the physical test,
  • Be engaged in a restricted diet program (e.g. weight loss diet),
  • Have any skin sensitivity or diseases (e.g. erysipelas, eczema, dermatitis, psoriasis and urticaria) in the irradiated area that may be aggravated by PBMT.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: placebo PBMT
Participants will be received placebo PBMT immediately before physical tests.
Device: Placebo
Participants will be received placebo PBMT on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Active Comparator: 300 J PBMT
Participants will be received PBMT at 300 J immediately before physical tests.
Device: 300 J
Participants will be received PBMT at 300 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Active Comparator: 600 J PBMT
Participants will be received PBMT at 600 J immediately before physical tests.
Device: 600 J
Participants will be received PBMT at 600 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)
Active Comparator: 1260 J PBMT
Participants will be received PBMT at 1260 J immediately before physical tests.
Device: 1260 J
Participants will be received PBMT at 1260 J on the quadriceps muscle of both legs, immediately before physical tests, using a device containing 200 LEDs (100 red and 100 infrared)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Countermovement vertical jump (CMJ)
Time Frame: 10 minutes
The CMJ test will be performed on a force platform (BIOMEC400-412, EMG System to Brazil Ltda, São Paulo, Brazil) to assess the flight time. Participants will perform three CMJs, interspersed with 1 min of rest, and the highest flight time will be used as an indicator of muscle power. The test will began with the participant standing, knees extended, and hands fixed on the iliac crest region (hips). The participant then will flexed their legs at an angle of approximately 90º and then quickly extended their legs to maximize the height of the jump. Hands will be kepted on hips throughout the jump.
10 minutes
Repetitions-to-failure
Time Frame: 10 minutes
The repetitions-to-failure test in the 45º leg press exercise consists of 3 sets at 70% of 1RM, with a 60-s rest interval between each set. Participants will perform as many repetitions as possible until momentary failure (i.e., when the participant is unable to complete the concentric portion of their current repetition across the full range of motion despite using maximal effort), and the maximum number of repetitions in each set will be recorded.
10 minutes
Fatigue index (FI)
Time Frame: 10 minutes
The fatigue index (FI) will be determined by the equation: [(REPS3 - REPS1)/REPS1]*100, where: REPS3 = number of repetitions in set 3, multiplied by the load lifted, and REPS1 = number of repetitions in set 1, multiplied by the load lifted. The higher the FI value (%), the higher the level of muscle fatigue.
10 minutes
Rating of perceive exterion (RPE)
Time Frame: 10 minutes
Rating of perceived exertion (RPE) will be recorded immediately after completion of each set using the OMNI-RES scale. The participants will be instructed to report the perceived exertion value by indicating a number on the OMNI-RES scale (0 for ''no effort'' and 10 for ''maximal effort'') that best represented their momentary exertion.
10 minutes
Maximum voluntary isometric contraction (MVIC)
Time Frame: 10 minutes
The MVIC test for the leg extension exercise (bilateral) will be performed using an isometric dynamometer (CEFISE Biotechnology, São Carlos, Brazil). Briefly, participants will perform three MVICs at 120º of knee flexion (180º = full extension) lasting 5 s, interspersed with 5 s of rest. Participants will be instructed and verbally encouraged to exert maximum force during all attempts. The highest value obtained for peak and mean torque of the three MVICs will be used for the analysis.
10 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universidade Norte do Paraná

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 15, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 18, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 16, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 16, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 20, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 7, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Photobiomodulation and futsal

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings